New rectal gel could offer On-Demand HIV protection without daily pills

NCT ID NCT06560684

Completed Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two ways to prevent HIV: a rectal gel used before sex and daily pills. About 150 men will try each method for 8 weeks to see which is safer, easier to use, and more acceptable. The goal is to give people more choices for on-demand HIV prevention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOFOVIR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TENOFOVIR

Contacts and locations

Show contact details

Locations

Alabama CRS (Site ID# 31788)

Birmingham, Alabama, 35222, United States
Chapel Hill CRS (3201)

Chapel Hill, North Carolina, 27599-7215, United States
Fenway Health (FH) CRS

Boston, Massachusetts, 02215-4302, United States
Hope Clinic CRS

Lawrenceville, Georgia, 30046, United States
Johns Hopkins University CRS

Baltimore, Maryland, 21287, United States
UCLA CARE Center CRS

Los Angeles, California, 90035, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States
Weill Cornell Chelsea CRS

New York, New York, 10011, United States